Use Of Post-Transplant Cyclophosphamide In One-Antigen Mismatched Unrelated Donor Transplantation Results In Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study On Behalf Of The Acute Leukemia Working Party Of The Ebmt

Introduction. In the absence of an HLA-identical sibling or a matched unrelated donor, whether to prefer a Haploidentical (Haplo) or a one antigen mismatched unrelated donor (MMUD) for allogeneic hematopoietic cell transplantation (HCT) remains an unanswered question. Implementation of graft-versus-host disease (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCY) was initially pioneered in the Haplo and then also extended to MMUD setting, resulting in low rates of GVHD.